SCHEMBL7046331

SCHEMBL7046331

COc1nn(-c2ccc(NC(=O)NC3Cc4ccccc4C3)c(C)c2)c(=O)o1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 3/20 0.61
FAAH O00519 2/20 0.61
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
MAPK14 Q16539 2/20 0.43
MAPK13 O15264 1/20 0.43
MAPK12 P53778 1/20 0.43
MAPK11 Q15759 1/20 0.43
MAPT P10636 2/20 0.42
ABHD16A O95870 2/20 0.42
LPL P06858 1/20 0.41
LIPC P11150 1/20 0.41
LIPE Q05469 1/20 0.41
KDM4E B2RXH2 2/20 0.40
LMNA P02545 3/20 0.39
POLB P06746 2/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
ALDH1A1 P00352 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7571649 0.81 MGLL (0.72) MGLLFAAHMAPTABHD16ALPL
SCHEMBL7045989 0.78 MGLL (0.66) MGLLFAAHMAPTABHD16ALPL
SCHEMBL7046095 0.78 MGLL (0.74) MGLLFAAHKMT2AABHD16ALPL
SCHEMBL7656177 0.77 MGLL (0.61) MGLLFAAHABHD16ALPLLIPC
SCHEMBL29499689 0.76 MGLL (1.00) MGLLFAAHABHD16ALPLLIPC
SCHEMBL7042914 0.76 MGLL (1.00) MGLLFAAHABHD16ALPLLIPC
SCHEMBL7047839 0.76 MGLL (0.58) MGLLFAAHMEN1KMT2AMAPK14
SCHEMBL7656723 0.75 MGLL (0.62) MGLLFAAHKMT2AMAPTABHD16A
SCHEMBL7045977 0.75 MGLL (0.62) MGLLFAAHKMT2AMAPTABHD16A
SCHEMBL6615026 0.75 MGLL (0.75) MGLLFAAHMAPTABHD16ALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase AVENTIS PHARMA DEUTSCHLAND GMBH 2003-12-25 US disclosed
US-6369088-B2 ANTIDIABETIC AGENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-09 US disclosed
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals CNR1, PTGER1, CNR2 MGLL 1542/4885FAAH 46/4885MEN1 3352/4885
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase PNLIP, CEL, LIPE MGLL 10/4885FAAH 142/4885MEN1 4309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.